The use of aminoglycosides in newborn infants

Paediatric and Perinatal Drug Therapy

Volumn 2, Issue 1, 1998, Pages 48-56

  De Hoog, Matthijs ^a   Mouton, Johan W ^a   Van Den Anker, John N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003164731     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. Waksman SA, Bugie E, Schatz A. Isolation of antibiotic substances from soil microorganisms with special reference to streptothricin and streptomycin. Proc Staff Meet Mayo Clin 1944;19:537-548.
2. Klein JO, Michael Marcy S. Bacterial sepsis and meningitis. In: Remington JS, Klein JO (Eds): Infectious diseases of the fetus and newborn infant, WB Saunders & Company, 1995; 836.
3. Fanaroff AA, Korones SB, Wright LL. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med 1994; 330: 1107-1113.
4. Gladstone IM, Ehrenkranz RA, Edberg SC, Baltimore RS. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990; 9: 819-825.
5. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992;327:213-2I9.
6. de Louvois J, Dagan R, Tessin I. A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases - Neonatal Sepsis Study Group. Eur J Pediatr 1992; 151:876-884.
7. Anonymous. Early neonatal drug utilization in preterm newborns in neonatal intensive care units. Italian Collaborative Group on Preterm Delivery. Dev Pharmacol Ther 1988; 11 : 1-7.
8. Gyselynck AM, Forrey A, Cutler R. Pharmacokinetics ofgentamicin: Distribution and plasma and renal clearance. J Infect Dis 1971; 124(Suppl 124): 70-76.
9. Van den Anker JN. The effect of renal function on clinical pharmacokinetics in the newborn. Rotterdam: Erasmus University, 1995:31.
10. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol 1995; 39:597-603.
11. Siegel JD, McCracken GH, Jr., Thomas ML, Threlkeld N. Pharmacokinetic properties of netilmicin in newborn infants. Antimicrob Agents Chemother 1979; 15:246-253.
12. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997; 17:27-33.
13. Sawchuk R, Zaske D. Pharmacokinetic dosage regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. JPharmacokinetBiopharm 1976; 4:183-195.
14. Evans WE, Feldman S, Barker LF, Ossi M, Chaudhary S. Use of gentamicin serum levels to individualise therapy in children. J Pediatr 1978; 93:133-137.
15. Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F. Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther 1991 ; 50: 55-65.
16. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygénation. Antimicrob Agents Chemother 1989; 33:817-819.
17. McCracken GH, Jr., Chrane DF, Thomas ML. Pharmacologie evaluation of gentamicin in newborn infants. J Infect Dis 1971 ; 124: Suppl: 214-219.
18. McCracken GH, West NR, Horton LJ. Urinary excretion of gentamicin in the neonatal period. J Infect Dis 1971; 123: 257-262.
19. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther 1985; 38:680-685.
20. Brion LP, Fleischman AR, Schwanz GJ. Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol 1991 ; 5:675-679.
21. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther 1988; 11: 173-179.
22. Pons G, d'Athis P, Rey E, et al. Gentamicin monitoring in neonates.TherDrugMonit 1988; 10:421-427.
23. Rodvold KA, Gentry ÇA, Plank GS, Kraus DM, Nickel E, Gross JR. Prediction of gentamicin concentrations in neonates and infants using a Bayesian pharmacokinetic model. Dev Pharmacol Ther 1993 ; 20:211 -219.
24. Keyes PS, Johnson CK, Rawlins TD. Predictors of trough serum gentamicin concentrations in neonates. Am J Dis Child 1989; 143:1419-1423.
25. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19:280-318.
26. Van den Anker JN, De Groot R, Broerse HM et al. Assessment of glomerular filtration rate in preterm infants by serum creatinine: comparison with inulin clearance. Pediatrics 1995; 96: 1156-1158.
27. Davison JM, Dunlop W, Ezimokhai M. 24-hour creatinine clearance during the third trimester of normal pregnancy. Br J Obstet Gynaecol 1980; 87:106-109.
28. MacGowan A, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother 1994;34:829-837.
29. Miranda JC, Schimmel MM, James LS, Spinell! W, Rosen TS. Gentamicin kinetics in the neonate. Pediatr Pharmacol (New York) 1985; 5:57-61.
30. Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixedeffects model. Pharmacotherapy 1992; 12:178-182.
31. Izquierdo M, Lanao JM, Cervero L, Jimenez N V, DominguezGil A. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992;14:177-183.
32. Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol 1993; 44: S23-S25.
33. Williams BS, Ransom JL, Gal P, Carlos RQ, Smith M, Schall SA. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med I997; 25:273-275.
34. van den Anker JN, Hop WCJ, De Groot R. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 1994; 36: 578-581.
35. Bueva A, Guignard JP. Renal function in preterm neonates. Pediatr Res 1994; 36:572-577.
36. Bidiwala KS, Lorenz JM, Kleinman LI. Renal function correlates of postnatal diuresis in preterm infants. Pediatrics 1988; 82:50-58.
37. Faura CC, Garcia MR, Horga JF. Changes in gentamicin serum levels and pharmacokinetic parameters in the newborn in the course of treatment with aminoglycoside. Ther Drug Monit 1991; 13:277-280.
38. Sardemann H, Colding H, Hendel J, Kampmann JP, Hvidberg EF, Vejlsgaard R. Kinetics and dose calculations of amikacin in the newborn. Clin Pharmacol Ther 1976; 20:59-66.
39. Kildoo C, Modanlou HD, Komatsu G, Harralson A, Hodding J. Developme'ntal pattern of gentamicin kinetics in very low birth weight (VLBW) sick infants. Dev Pharmacol Ther 1984; 7: 345-356.
40. Nahata MC, Powell DA, Durrell DE, Miller MA, Glazer JP. Intrapatient variation in tobramycin kinetics in low birth weight infants during first postnatal week. Eur J Clin Pharmacol 1984; 26:647-649.
41. Van den Anker JN, Hop WCJ, Schoemaker RC, Van der Heijden AJ, Neijens HJ, De Groot R. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br J Clin Pharmacol 1995; 40: 439-443.
42. Watterberg KL, Kelly HW, Johnson JD, Aldrich M, Angélus P. Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1500 g) babies. Dev Pharmacol Ther 1987; 10: 107-117.
43. Van den Anker JN, Kearns GL. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus (letter). Crit Care Med 1997;25:1933-1934.
44. Gal P, Ransom JL, Weaver RL. Gentamicin in neonates: the need for loading doses. Am J Perinatol 1990; 7:254-257.
45. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygénation. Ther Drug Monit 1994; 16:552-559.
46. Mitsuhashi S, Kawabe H. Aminoglycoside antibiotic resistance in bacteria. In: Whelton A, Neu HC, eds. The aminoglycosides. New York: Marcel Dekker, 1983:97.
47. Sanders CC, Sanders WE, Goering RV. In vitro studies with Sch 21420 and Sch 22591 : activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother 1978; 14: 178.
48. Krediet TG, Fleer A, Gerards LJ. Development of resistance to aminoglycosides among coagulase-negative staphylococci and enterobacteriaceae in a neonatal intensive care unit. J Hosp Infect 1993; 24:39-46.
49. de Champs C, Franchineau P, Gourgand JM, Loriette Y, Gaulme J, Sirot J. Clinical and bacteriological survey after change in aminoglycoside treatment to control an epidemic of Enterobacter cloacae. J Hosp Infect 1994; 28:219-229.
50. Friedland IR, Funk E, Khoosal M, Klugman KP. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother 1992; 36: 1596-1600.
51. Bryan CS, John JF, Jr., Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child 1985; 139: 1086-1089.
52. Aebi C. Empiric antimicrobial therapy in severe neonatal and pédiatrie infections (abstract), Third European Congress on Pédiatrie and Neonatal Intensive Care, Bern, 1997.
53. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995; 26:1477-1487.
54. Kaloyanides GJ, Pastoriza-Munoz E. Aminoglycoside nephrotoxicity. Kidney Int 1980; 18:571-582.
55. Giuliano RA, Verpooten GA, Verbist L, Wedeen R, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236:470-475.
56. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22-27.
57. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991 ; 27, Suppl. C: 41-47.
58. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1996; 14: 1029-1038.
59. Barza M, loannidis J, Cappeleri J, Lau J. Single or multiple daily doses of aminoglycosides: a meta analysis. BMJ 1996; 312:338-344.
60. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645-663.
61. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [see comments]. Clin Infect Dis 1997; 24: 796-809.
62. Leititis JU, Zimmerhackl LB, Burghard R, Gordjani N, Brandis M. Evaluation of local renal function in newborn infants under tobramycin therapy. Dev Pharmacol Ther 1991; 17: 154-160.
63. Giapros VI, Andronikou S, Cholevas VI, Papadopoulou ZL. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9:163-166.
64. Andronikou S, Giapros VI, Cholevas VI, Papadopoulou ZL. Effect of aminoglycoside therapy on renal function in full-term infants. Pediatr Nephrol 1996; 10:766-768.
65. Parini R, Rusconi F, Cavanna G, Vigliani E, Cornacchia L, Assael BM. Evaluation of the renal and auditory function of neonates treated with amikacin. Dev Pharmacol Ther 1982; 5: 33-46.
66. Langhendries JP, Battisti O, Bertrand JM, et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993; 20: 220-230.
67. Gordjani N, Burghard R, Muller D et al. Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin. Pediatr Nephrol 1995; 9:419-422.
68. Giacoia GP, Schentag JJ. Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants. J Pediatr 1986; 109:715-719.
69. Gouyon JB, Aujard Y, Abisror A, et al. Urinary excretion of Nacetyl-glucosaminidase and beta-2-microglobuIin as early markers of gentamicin nephrotoxicity in neonates. Dev Pharmacol Ther 1987; 10: 145-152.
70. Rajchgot P, Prober CG, Soldin S et al. Aminoglycoside-related nephrotoxicity in the premature newborn. Clin Pharmacol Ther 1984; 35:394-401.
71. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31:570-574.
72. Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy 1995; 15:297-316.
73. Ernfors P, Canlon B. Aminoglycoside excitement silences hearing [news; comment]. Nat Med 1996; 2:1313-1314.
74. Basile AS, Huang JM, Xie C, Webster D, Berlin C, Skolnick P. A'-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss [see comments]. Nat Med 1996; 2: 1338-1343.
75. Kohelet D, Usher M, Arbel E, Arlazoroff A, Goldberg M. Effect of gentamicin on the auditory brainstem evoked response in term infants: a preliminary report. Pediatr Res 1990; 28:232-234.
76. McCormack JP, Jewesson PJ. A critical re-evaluation of the 'therapeutic range' of aminoglycosides. Clin Infect Dis 1992; 14:320-339.
77. McCracken GH, Jr. Aminoglycoside toxicity in infants and children. Am J Med 1986; 80:172-178.
78. Borradori C, Fawer CL, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 1997;71:1-10.
79. Cox C, Hack M, Metz D, Fanaroff A. Auditory brainstem evoked responses for screening very low birthweight infants ( VLB W)-Effects of gentamicin and neonatal risk factors on maturation. Ped Research 1979; 13:524A.
80. Chayasirisobhon S, Yu L, Griggs L, Westmoreland SJ, Leu N. Recording of brainstem evoked potentials and their association with gentamicin in neonates. Pediatr Neurol 1996; 14: 277-280.
81. Finitzo-Hieber T, McCracken GH, Jr, Brown KC. Prospective controlled evaluation of auditory function in neonates given netilmicinoramikacin.JPediatr1985; 106: 129-136.
82. Bernard PA. Freedom from ototoxicity in aminoglycoside treated neonates: a mistaken notion. Laryngoscope 1981 ; 91 : 1985-1994.
83. Salamy A, Eldredge L, Tooley WH. Neonatal status and hearing loss in high-risk infants [see comments]. J Pediatr 1989; 114:847-852.
84. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides [see comments]. J Antimicrob Chemother 1989; 24:281-293.
85. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with Gramnegative bacteremia.J Infect Dis 1984; 149:443-48.
86. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
87. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents and Chemother 1987;31: 1054-1060.
88. Semchuk W, Borgmann J, Bowman L. Determination of a gentamicin loading dose in neonates and infants. Ther Drug Monit 1993; 15:47-51.
89. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross J W, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39:650-655.
90. Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34:265-268.
91. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997; 62:392-399.
92. Bloome MR, Warren AJ, Ringer L, Walker PC. Evaluation of an empirical dosing schedule for gentamicin in neonates. Drug InlellClinPharm 1988; 22:618-622.
93. Semchuk W, Shevchuk YM, Sankaran K, Wallace SM. Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates. Biol Neonate 1995; 67: 13-20.
94. Ettlinger JJ, Bedford KA, Levering AM, Reeves DS, Speidel BD, MacGowan AP. Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates. J Antimicrob Chemother 1996; 38:499-505.
95. Watterberg KL, Kelly HW, Angélus P, Backstrom C. The need for a loading dose of gentamicin in neonates. Ther Drug Monit 1989;11:16-20.
96. Wagner BP, Pfenninger J. Once daily dosing of netilmicin in neonatal and pédiatrie intensive care. Intensive Care Med 1994; 20:365-367.
97. de Man P, Verhoeven BAN, Mouton JW, van den Anker JN. Tobramycin in newborn infants: the need for therapeutic drug monitoring in individual patients. Second International Pédiatrie Infectious Disease Conference, Napa Valley, California, 1997.
98. Skopnik H, Wallraf R, Nies B, Troster K, Heimann G. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992; 67:57-61.
99. Skopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J 1995; 14:71-72.
100. Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther 1993; 20:167-173.
101. Nakae S, Yamada M, Ito T et al. Gentamicin dosing and pharmacokinetics in low birth weight infants. Tohoku J Exp Med 1988; 155:213-223.
102. Koren G, Leeder S, Harding E, Jacques D, MacLeod SM. Optimization of gentamicin therapy in very low birth weight infants. Pediatr Pharmacol (New York) 1985; 5:79-87.
103. Dahl LB, Melby K, Gutteberg TJ, Storvold G. Serum levels of ampicillin and gentamycin in neonates of varying gestational age. Eur J Pediatr 1986; 145:218-221.
104. Isemann BT, Kotagal UR, Mashni SM, Luckhaupt El, Johnson CJ. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Ther Drug Monit 1996; 18: 549-555.
105. Faura CC, Feret MA, Horga JF. Monitoring serum levels of gentamicin to develop a new regimen for gentamicin dosage in newborns. Ther Drug Monit 1991; 13:268-276.
106. Granati B, Assael BM, Chung M, et al. Clinical pharmacology of netilmicin in preterni and term newborn infants. J Pediatr 1985; 106:664-669.
107. Kühn RJ, Nahata MC, Powell DA, Bickers RG. Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharm 1986; 29:635-637.
108. Nahata MC, Powell DA, Durrell DE, Miller MC, Glazer JP. Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. J Antimicrob Chemother 1984; 14: 59-65.
109. Nahata MC, Powell DA, Durrell DE, Miller MA. Tobramycin pharmacokinetics in very low birth weight infants. Br J Clin Pharmacol 1986; 21:325-327.
110. Tsai CH, Tsai FJ. Auditory brainstem responses in term neonates treated with gentamicin. Acta Paediatr Sin 1992; 33: 417-122.